NO344992B1 - Anti-GM-CSF antistoffer og anvendelser for disse - Google Patents

Anti-GM-CSF antistoffer og anvendelser for disse

Info

Publication number: NO344992B1
Authority: NO; Norway
Prior art keywords: csf antibodies; csf; antibodies
Prior art date: 2005-05-18

Application number

NO20076437A

Other languages

English (en)

Other versions

NO20076437L (no

Inventor

Stefan Steidl

Elisabeth Thomassen-Wolf

Original Assignee

Morphosys Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-18

Filing date

2007-12-13

Publication date

2020-08-17

2007-12-13 Application filed by Morphosys Ag filed Critical Morphosys Ag

2007-12-13 Publication of NO20076437L publication Critical patent/NO20076437L/no

2020-08-17 Publication of NO344992B1 publication Critical patent/NO344992B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20076437A 2005-05-18 2007-12-13 Anti-GM-CSF antistoffer og anvendelser for disse NO344992B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68200905P	2005-05-18	2005-05-18
PCT/EP2006/004696 WO2006122797A2 (en)	2005-05-18	2006-05-17	Anti-gm-csf antibodies and uses therefor

Publications (2)

Publication Number	Publication Date
NO20076437L NO20076437L (no)	2007-12-13
NO344992B1 true NO344992B1 (no)	2020-08-17

Family

ID=37114333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20076437A NO344992B1 (no)	2005-05-18	2007-12-13	Anti-GM-CSF antistoffer og anvendelser for disse

Country Status (26)

Country	Link
US (5)	US7867495B2 (no)
EP (4)	EP1888643B1 (no)
JP (2)	JP5295759B2 (no)
KR (1)	KR101308087B1 (no)
CN (2)	CN101218255B (no)
AR (1)	AR053608A1 (no)
AU (1)	AU2006249062B2 (no)
BR (1)	BRPI0610796B8 (no)
CA (1)	CA2608498C (no)
DK (2)	DK3620171T3 (no)
ES (2)	ES2527428T3 (no)
HK (1)	HK1114620A1 (no)
HR (2)	HRP20220755T3 (no)
HU (1)	HUE058876T2 (no)
IL (1)	IL187375A (no)
LT (1)	LT3620171T (no)
ME (1)	ME02059B (no)
NO (1)	NO344992B1 (no)
NZ (1)	NZ564027A (no)
PL (2)	PL3620171T3 (no)
PT (2)	PT1888643E (no)
RS (2)	RS53743B1 (no)
RU (1)	RU2447085C2 (no)
SI (2)	SI3620171T1 (no)
TW (1)	TWI477512B (no)
WO (1)	WO2006122797A2 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1874819B1 (en)	2005-04-18	2015-05-27	Amgen Research (Munich) GmbH	Antibody neutralizers of human granulocyte macrophage colony stimulating factor
CN101218255B (zh)	2005-05-18	2013-01-09	莫菲西斯公司	抗gm-csf抗体和其用途
JP4736037B2 (ja)	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR101395515B1 (ko) *	2006-02-08	2014-05-14	모르포테크, 인크.	항원성 ｇｍ-ｃｓｆ 펩티드 및 ｇｍ-ｃｓｆ에 대한 항체
WO2008063898A2 (en) *	2006-11-08	2008-05-29	Kalobios Pharmaceuticals, Inc.	Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en)	2006-11-21	2013-03-19	Kalobios Pharmaceuticals, Inc.	Methods of treating dementia using a GM-CSF antagonist
CA2670288C (en)	2006-11-21	2015-10-27	Kalobios Pharmaceuticals, Inc.	Methods of treating chronic inflammatory diseases using a gm-csf antagonist
AU2008253608A1 (en) *	2007-05-23	2008-11-27	Crc For Asthma And Airways Ltd	Neutralizing antibodies
TW200918553A (en) *	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
EP2217626A4 (en) *	2007-11-12	2011-06-22	Crc For Asthma And Airways Ltd	EPITOP FOR NEUTRALIZING ANTIBODIES
SI2215119T1 (sl) *	2007-11-13	2013-04-30	Evec Inc.	Monoklonska protitelesa, ki se veĹľejo na hGM-CSF, in medicinski sestavki, ki jih obsegajo
UA106036C2 (uk)	2007-11-26	2014-07-25	Баєр Інтеллекчуел Проперті Гмбх	Анти-мезотелінове антитіло та його застосування
EP2088432A1 (en) *	2008-02-11	2009-08-12	MorphoSys AG	Methods for identification of an antibody or a target
KR101852915B1 (ko) *	2008-04-28	2018-04-27	휴머니건, 아이엔씨.	과립구-대식세포 콜로니 자극 인자에 대한 항체
WO2009142738A2 (en) *	2008-05-21	2009-11-26	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
CA2729749A1 (en) *	2008-07-02	2010-01-07	Emergent Product Development Seattle, Llc	Tnf-a antagonist multi-target binding proteins
KR101799264B1 (ko)	2008-12-22	2017-11-20	더 유니버시티 오브 멜버른	골관절염 치료
RU2630969C2 (ru)	2008-12-22	2017-09-15	Де Юниверсити Оф Мельбурн	Лечение боли
SG175305A1 (en) *	2009-04-23	2011-11-28	Theraclone Sciences Inc	Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
UY32560A (es)	2009-04-29	2010-11-30	Bayer Schering Pharma Ag	Inmunoconjugados de antimesotelina y usos de los mismos
RU2539034C2 (ru) *	2009-05-05	2015-01-10	МорфоСис АГ	Лечение рассеянного склероза
CA2839513A1 (en) *	2011-07-06	2013-01-10	Morphosys Ag	Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
US9901079B2 (en) *	2011-08-18	2018-02-27	New York University	Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en)	2011-12-22	2013-06-27	Csl Limited	Method of treating inflammatory bowel disease
EP2843051B1 (en)	2012-04-23	2018-06-06	GeneFrontier Corporation	Anti-human cd69 antibody, and use thereof for medical purposes
EP3540438A1 (en) *	2012-08-17	2019-09-18	MorphoSys AG	Complex-specific antibodies and antibody fragments and its use
KR20210021153A (ko) *	2012-09-20	2021-02-24	모르포시스 아게	류마티스 관절염에 대한 치료
SG10201803778PA (en) *	2012-09-20	2018-06-28	Morphosys Ag	Treatment for rheumatoid arthritis
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en)	2012-10-31	2019-05-22	Takeda GmbH	Lyophilized formulation comprising gm-csf neutralizing compound
CN104937099B (zh)	2012-11-09	2018-03-30	基因先端领域株式会社	用于治疗癌症的抗adam28抗体
US20160024200A1 (en) *	2013-03-14	2016-01-28	John Schrader	Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
KR20220045064A (ko)	2013-08-30	2022-04-12	다케다 야쿠힌 고교 가부시키가이샤	류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
AR100268A1 (es)	2014-05-07	2016-09-21	Takeda Gmbh	Formulación líquida que comprende compuesto neutralizante de gm-csf
JP6490419B2 (ja) *	2014-12-24	2019-03-27	学校法人関西医科大学	制御性ｔ細胞分化誘導剤
GB201503139D0 (en) *	2015-02-25	2015-04-08	Univ Leicester	Diagnostic and therapeutic target
JP6783983B2 (ja)	2015-03-06	2020-11-11	ジーンフロンティア株式会社	抗ヒト膜型ａｄａｍ２８抗体
CN107840886B (zh) *	2016-09-19	2020-11-10	天境生物科技(上海)有限公司	Gm-csf抗体及其用途
MX2019003019A (es) *	2016-09-19	2019-09-19	I Mab	Anticuerpos anti-gm-csf y usos de los mismos.
US11130805B2 (en)	2017-10-02	2021-09-28	Humanigen, Inc.	Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US11673962B2 (en)	2017-10-02	2023-06-13	Humanigen, Inc.	Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
US10899831B2 (en)	2017-10-02	2021-01-26	Humanigen, Inc.	Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en)	2017-10-02	2021-02-23	Humanicen, Inc.	Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11655293B2 (en)	2018-02-22	2023-05-23	Universitat Zurich	Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en)	2018-09-14	2020-03-18	Universität Zürich	Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en)	2018-10-17	2021-08-03	University Of Connecticut	Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
CA3117380A1 (en)	2018-11-09	2020-05-14	Kiniksa Pharmaceuticals, Ltd.	Treatment for giant cell arteritis
CN113677356A (zh) *	2019-01-07	2021-11-19	湖南思为康医药有限公司	用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
JP2022535062A (ja)	2019-06-03	2022-08-04	キニクサファーマシューティカルズ，リミテッド	Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
WO2021188409A1 (en)	2020-03-15	2021-09-23	Kiniksa Pharmaceuticals, Ltd.	Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en)	2020-04-06	2021-10-14	Glaxosmithkline Intellectual Property Development Limited	Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
AU2021372454A1 (en)	2020-10-26	2023-06-22	Kiniksa Pharmaceuticals, Gmbh	Treatment of cancers with gm-csf antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997008320A1 (en) *	1995-08-18	1997-03-06	Morphosys Gesellschaft Für Proteinoptimierung Mbh	Protein/(poly)peptide libraries
WO2003068920A2 (en) *	2002-02-13	2003-08-21	Ludwig Institute For Cancer Research	Humanized gm-csf antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5747032A (en)	1990-08-10	1998-05-05	Amrad Corporation Limited	Monoclonal antibody to human granulocyte macrophage colony stimulating factor
CA2060741A1 (en)	1991-02-11	1992-08-12	Robert S. Greenfield	Gm-csf inhibiting oligopeptides
AUPP525198A0 (en)	1998-08-13	1998-09-03	Medvet Science Pty. Ltd.	Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
DE60041119D1 (de)	1999-07-20	2009-01-29	Morphosys Ag	Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
JP4555089B2 (ja)	2002-11-15	2010-09-29	モーフオテク・インコーポレーテツド	ｉｎｖｉｔｒｏ免疫感作により創製されたハイブリドーマからの抗体の高生産量の生成方法
DE602004021773D1 (de)	2004-05-05	2009-08-13	Micromet Ag	Herstellung eines einkettigen fv Antikörperfragments
CN101218255B (zh) *	2005-05-18	2013-01-09	莫菲西斯公司	抗gm-csf抗体和其用途

2006
- 2006-05-17 CN CN2006800249817A patent/CN101218255B/zh active Active
- 2006-05-17 KR KR1020077029189A patent/KR101308087B1/ko active IP Right Grant
- 2006-05-17 US US11/914,599 patent/US7867495B2/en active Active
- 2006-05-17 EP EP06742970.4A patent/EP1888643B1/en active Active
- 2006-05-17 EP EP16162171.9A patent/EP3150221A1/en not_active Withdrawn
- 2006-05-17 PL PL19180152.1T patent/PL3620171T3/pl unknown
- 2006-05-17 HU HUE19180152A patent/HUE058876T2/hu unknown
- 2006-05-17 DK DK19180152.1T patent/DK3620171T3/da active
- 2006-05-17 AU AU2006249062A patent/AU2006249062B2/en active Active
- 2006-05-17 LT LTEP19180152.1T patent/LT3620171T/lt unknown
- 2006-05-17 NZ NZ564027A patent/NZ564027A/en unknown
- 2006-05-17 RS RS20150018A patent/RS53743B1/en unknown
- 2006-05-17 ME MEP-2015-5A patent/ME02059B/me unknown
- 2006-05-17 BR BRPI0610796A patent/BRPI0610796B8/pt active IP Right Grant
- 2006-05-17 ES ES06742970.4T patent/ES2527428T3/es active Active
- 2006-05-17 EP EP11187236A patent/EP2468773A3/en not_active Withdrawn
- 2006-05-17 RU RU2007147870/10A patent/RU2447085C2/ru active
- 2006-05-17 CN CN201210510236.0A patent/CN103087190B/zh active Active
- 2006-05-17 SI SI200632423T patent/SI3620171T1/sl unknown
- 2006-05-17 EP EP19180152.1A patent/EP3620171B1/en active Active
- 2006-05-17 SI SI200631880T patent/SI1888643T1/sl unknown
- 2006-05-17 ES ES19180152T patent/ES2918209T3/es active Active
- 2006-05-17 RS RS20220609A patent/RS63382B1/sr unknown
- 2006-05-17 HR HRP20220755TT patent/HRP20220755T3/hr unknown
- 2006-05-17 CA CA2608498A patent/CA2608498C/en active Active
- 2006-05-17 PL PL06742970T patent/PL1888643T3/pl unknown
- 2006-05-17 WO PCT/EP2006/004696 patent/WO2006122797A2/en active Application Filing
- 2006-05-17 PT PT67429704T patent/PT1888643E/pt unknown
- 2006-05-17 PT PT191801521T patent/PT3620171T/pt unknown
- 2006-05-17 DK DK06742970.4T patent/DK1888643T3/en active
- 2006-05-17 JP JP2008511635A patent/JP5295759B2/ja active Active
- 2006-05-18 AR ARP060102017A patent/AR053608A1/es unknown
- 2006-05-18 TW TW095117745A patent/TWI477512B/zh active
2007
- 2007-11-14 IL IL187375A patent/IL187375A/en active IP Right Grant
- 2007-12-13 NO NO20076437A patent/NO344992B1/no unknown
2008
- 2008-09-05 HK HK08109862.8A patent/HK1114620A1/xx unknown
2010
- 2010-09-16 US US12/923,363 patent/US9751939B2/en active Active
2013
- 2013-03-06 JP JP2013044573A patent/JP5769744B2/ja active Active
2015
- 2015-01-09 HR HRP20150023TT patent/HRP20150023T1/hr unknown
2016
- 2016-12-21 US US15/386,152 patent/US10377820B2/en active Active
2019
- 2019-06-17 US US16/442,779 patent/US11028165B2/en active Active
2021
- 2021-05-07 US US17/314,198 patent/US20210347879A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997008320A1 (en) *	1995-08-18	1997-03-06	Morphosys Gesellschaft Für Proteinoptimierung Mbh	Protein/(poly)peptide libraries
WO2003068920A2 (en) *	2002-02-13	2003-08-21	Ludwig Institute For Cancer Research	Humanized gm-csf antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KREBS B. ET AL. "High-throughput generation and engineering of recombinant human antibodies." Journal of Immunological Methods. August 2001, Vol. 254, Nr. 1-2, side 67-84., Dated: 01.01.0001 *
RAUCHENBERGER R. ET AL. "Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3." Journal of Biological Chemistry. Oktober 2003, Vol. 278, Nr. 30, side 38194-38205., Dated: 01.01.0001 *

Also Published As

Publication number	Publication date
WO2006122797A3 (en)	2007-02-15
BRPI0610796A2 (pt)	2010-11-09
HRP20150023T1 (hr)	2015-02-27
RU2007147870A (ru)	2009-06-27
WO2006122797B1 (en)	2007-04-19
PL1888643T3 (pl)	2015-04-30
KR101308087B1 (ko)	2013-10-16
RS53743B1 (en)	2015-06-30
SI3620171T1 (sl)	2022-09-30
TWI477512B (zh)	2015-03-21
RS63382B1 (sr)	2022-08-31
EP1888643A2 (en)	2008-02-20
US20110045000A1 (en)	2011-02-24
CN103087190B (zh)	2016-08-03
JP5295759B2 (ja)	2013-09-18
TW200716674A (en)	2007-05-01
CN101218255A (zh)	2008-07-09
BRPI0610796B1 (pt)	2020-01-21
IL187375A0 (en)	2008-02-09
NO20076437L (no)	2007-12-13
HUE058876T2 (hu)	2022-09-28
AR053608A1 (es)	2007-05-09
PL3620171T3 (pl)	2022-08-08
US10377820B2 (en)	2019-08-13
US11028165B2 (en)	2021-06-08
EP3620171B1 (en)	2022-04-20
EP2468773A3 (en)	2012-09-19
HK1114620A1 (en)	2008-11-07
ES2527428T3 (es)	2015-01-23
SI1888643T1 (sl)	2015-03-31
DK3620171T3 (da)	2022-06-07
US20170218061A1 (en)	2017-08-03
KR20080015008A (ko)	2008-02-15
HRP20220755T3 (hr)	2022-09-02
EP2468773A2 (en)	2012-06-27
NZ564027A (en)	2011-06-30
US20090053213A1 (en)	2009-02-26
PT1888643E (pt)	2015-01-14
JP5769744B2 (ja)	2015-08-26
ME02059B (me)	2015-05-20
ES2918209T3 (es)	2022-07-14
US9751939B2 (en)	2017-09-05
CA2608498C (en)	2017-04-04
US7867495B2 (en)	2011-01-11
AU2006249062B2 (en)	2012-12-20
BRPI0610796B8 (pt)	2021-05-25
CN101218255B (zh)	2013-01-09
RU2447085C2 (ru)	2012-04-10
LT3620171T (lt)	2022-06-10
EP3620171A1 (en)	2020-03-11
DK1888643T3 (en)	2015-01-05
EP3150221A1 (en)	2017-04-05
US20200024340A1 (en)	2020-01-23
CN103087190A (zh)	2013-05-08
CA2608498A1 (en)	2006-11-23
IL187375A (en)	2012-06-28
JP2008545632A (ja)	2008-12-18
JP2013116912A (ja)	2013-06-13
WO2006122797A2 (en)	2006-11-23
PT3620171T (pt)	2022-06-30
US20210347879A1 (en)	2021-11-11
AU2006249062A1 (en)	2006-11-23
EP1888643B1 (en)	2014-10-29

Publication	Publication Date	Title
NO344992B1 (no)	2020-08-17	Anti-GM-CSF antistoffer og anvendelser for disse
CY2019041I2 (el)	2020-05-29	Τροποποιημενα αντισωματα εναντι il-23
IL272883A (en)	2020-04-30	Monoclonal antibodies and their uses
DK1994055T3 (da)	2014-08-25	Anti-5t4-antistoffer og anvendelser deraf
NO20080692L (no)	2008-04-03	SP35 antistoffer og anvendelse derav
LTC1963368I2 (lt)	2018-01-10	Anti-il-17 antikūnai
DK2059535T3 (da)	2014-01-13	Prlr-specifikt antistof og anvendelser deraf
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
IL187710A0 (en)	2008-08-07	Anti-trkb monoclonal antibodies and uses thereof
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
IL191820A0 (en)	2008-12-29	Anti-ox40l antibodies and methods using same
DK2907827T3 (da)	2019-01-02	Humaniserede anti-faktor D-antistoffer og anvendelser deraf
IL222922A (en)	2015-07-30	Antibodies against neurophilin-1 and their use
ATE483732T1 (de)	2010-10-15	Madcam-antikörper
DK2152748T3 (da)	2013-11-04	Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
DK1855841T3 (da)	2010-04-12	Slibeartikler og fremgangsmåder til fremstilling af disse
DK2209806T3 (da)	2012-09-17	Anti-hepcidin-antistoffer og anvendelser deraf
DK1976884T3 (da)	2013-02-25	Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
DK1954713T3 (da)	2013-02-11	Modificerede grønfluorescerende proteiner og fremgangsmåder til anvendelse af samme
DE602006021285D1 (de)	2011-05-26	Mikrotomklinge
DE602006017520D1 (de)	2010-11-25	Immuntestverfahren und reagens dafür
ATE484750T1 (de)	2010-10-15	Immuntestverfahren und reagens dafür
GB0507219D0 (en)	2005-05-18	Antibody and uses thereof

Legal Events

Date	Code	Title	Description
2017-06-26	CREP	Change of representative	Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO
2019-04-15	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: MORPHOSYS AG, DE